Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Doctors and the DEA Free full text
Your Article Summary
See Latest ArticlesEffects of EGFR tyrosine kinase inhibitor erlotinib in prostate cancer cells in vitro
The Prostate, 06/30/09
Festuccia C et al. - In a study to determine why EGFR inhibitors been so ineffective in human prostate cancer (PCa), the results seem to suggest that a low EGFR/Her2 ratio and PTEN absence are the main factors responsible of erlotinib inefficacy. The inhibition of EGFR could have important antitumor effects in hormone-naive rather than in hormonally treated pts.
Methods- The effectiveness of erlotinib was assessed in a wide range of PCa cells (wild type or engineered to overexpress peculiar proteins including androgen receptor and PTEN).
- The effectiveness of erlotinib was inversely correlated to the EGFR/Her2 ratio rather than EGFR/p-EGFR or Her2/p-Her2 levels.
- Chronic treatment with bicalutamide induced overexpression of Her2 and reduction of EGFR/Her2 ratio and this was associated with increased Akt and Erk activity.
- In these treatment conditions, a reduced efficacy of erlotinib was observed.
- At the same time, an increased efficacy vs erlotinib was documented in cancer cells chronically exposed to DHT.
- In these culture conditions, low levels of Her2 and increased EGFR/Her2 ratio were evidenced.
Related Articles
Using erlotinib to treat patients with non-small cell lung cancer who continue to smoke
Lung Cancer, 10/07/09
Relevance Score: 87%
Molecular mechanism underlying the synergistic interaction between trifluorothymidine and the epidermal growth factor receptor inhibitor erlotinib in human colorectal cancer cell lines
Cancer Science, 11/16/09
Relevance Score: 85%
Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer
Journal of Clinical Oncology, 11/03/09
Relevance Score: 85%
Phase II Study of Erlotinib in Patients With Locally Advanced or Metastatic Papillary Histology Renal Cell Cancer: SWOG S0317
Journal of Clinical Oncology, 11/12/09
Relevance Score: 83%
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different
Anti-Cancer Drugs, 10/19/09
Relevance Score: 80%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Current status of chemotherapy in risk-adapted management for metastatic testicular germ cell cancer
Cancer Science, 12/03/09
Cizolirtine Citrate Is Safe and Effective for Treating Urinary Incontinence Secondary to Overactive Bladder: A Phase 2 Proof-of-Concept Study
European Urology, 12/03/09
Naftopidil as medical expulsive therapy for distal ureteral stone
Indian Journal of Urology, 12/03/09
Today in Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Defining the Optimal Treatment for Clinical Stage I Nonseminomatous Germ Cell Testicular Cancer Using Decision Analysis
Journal of Clinical Oncology, 12/04/09
Laparoscopic versus open radical cystectomy for the management of bladder cancer: Mid-term oncological outcome
International Journal of Urology, 12/04/09
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
The Prostate, 12/04/09
Today in Prostate...keeping you current
Receive free subspecialty "5-minute updates" via email
Periurethral injection of autologous adipose-derived stem cells for the treatment of stress urinary incontinence in patients undergoing radical prostatectomy: Report of two initial cases
International Journal of Urology, 12/04/09
Benign Prostatic Hyperplasia: Symptoms, Symptom Scores, and Outcome Measures
Urologic Clinics of North America, 12/04/09
Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus
The Prostate, 12/04/09
Article Search
Sponsor